CD38 and Miyoshi myopathy: Another approach, treatment with a bispecific CD38-CAR coupled with anti-BCMA single-chain variable fragment, resulted in an overall response in 14 (87.5%) r/r MM patients with manageable toxicity in phase 1 clinical trial [91].